– Results establish favorable safety profile and show the potential for efficacy with once-weekly dosing of a next generation GLP-2 analog – In head-to-head rat studies, apraglutide displayed a longer…
BASEL, Switzerland, Jan. 30, 2019 – Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced the appointments of Sandip…
BASEL, Switzerland, Jan. 16, 2019 — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced that the U.S. Food…
BASEL, Switzerland, Jan. 8, 2019 — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced that it has appointed…
BASEL, Switzerland, Nov. 29, 2018 — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating the root causes of rare conditions, today announced that the European Commission has granted Orphan Drug Designation for…
